GlucoNorm PM
... If this treatment program fails to reduce symptoms and/or blood glucose GlucoNorm® should be discontinued. The use of other oral blood glucose-lowering agent or insulin should be considered. Use of GlucoNorm® must be viewed by both the physician and patient as a treatment in addition to diet, and no ...
... If this treatment program fails to reduce symptoms and/or blood glucose GlucoNorm® should be discontinued. The use of other oral blood glucose-lowering agent or insulin should be considered. Use of GlucoNorm® must be viewed by both the physician and patient as a treatment in addition to diet, and no ...
Datasheet Methylprednisolone Sodium Succinate
... to severe pneumocystis carinii pneumonia when given in the first 72 hours of initial anti-pneumocystis treatment. Due to the increased rate of reactivation of tuberculosis in Aids patients, consideration should be given to the administration of anti-mycobacteria therapy if corticosteroids are used i ...
... to severe pneumocystis carinii pneumonia when given in the first 72 hours of initial anti-pneumocystis treatment. Due to the increased rate of reactivation of tuberculosis in Aids patients, consideration should be given to the administration of anti-mycobacteria therapy if corticosteroids are used i ...
ANAFRANIL® 25 mg Coated tablets, 75 mg Sustained
... Antidepressants increased the risk of suicidal thinking and behaviour (suicidality) in shortterm studies in children, adolescents and young adults less than 25 years old with depressive disorders and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality ...
... Antidepressants increased the risk of suicidal thinking and behaviour (suicidality) in shortterm studies in children, adolescents and young adults less than 25 years old with depressive disorders and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality ...
The use of rapid onset opioids for breakthrough cancer pain - e-ESO
... the last years, due to the rapid effect clinically observable 10–15 min after drug administration, obtainable in noninvasive forms. Not all drugs are suitable for transmucosal administration. Fentanyl is a potent and strongly lipophilic drug, which matches the characteristics to favour the passage t ...
... the last years, due to the rapid effect clinically observable 10–15 min after drug administration, obtainable in noninvasive forms. Not all drugs are suitable for transmucosal administration. Fentanyl is a potent and strongly lipophilic drug, which matches the characteristics to favour the passage t ...
Opioid-induced hyperalgesia and tolerance
... 25 patients with best results in deafferentation and mixed pain Initial dose average 1.1 mg/d increased by 6 months to 3.1 mg/d ...
... 25 patients with best results in deafferentation and mixed pain Initial dose average 1.1 mg/d increased by 6 months to 3.1 mg/d ...
LACHMANCONSULTANTSERVICES,INC Westbury, NY 11590
... The absolute bioavailability after a 10 mg oral dose of bisoprolol fuinai~ate is about 80%. The first pass metabolism of bisoprolol fiunarate is about 20% . The pharmacokineric profile of bisoprolol fumarate has been exaiuined following single doses and at steady state. Binding to serum proteins is ...
... The absolute bioavailability after a 10 mg oral dose of bisoprolol fuinai~ate is about 80%. The first pass metabolism of bisoprolol fiunarate is about 20% . The pharmacokineric profile of bisoprolol fumarate has been exaiuined following single doses and at steady state. Binding to serum proteins is ...
PPT
... Canada 2013 • In the very elderly (age ≥ 80), the target for SBP should be < 150 (grade C) • No changes for those age 65-79; ie goal remains at < 140/90 Europe 2013 • In elderly < 80 years old with SBP ≥160 mmHg there is solid evidence to reducing SBP to 150 and 140 mmHg (IA) • In fit elderly patien ...
... Canada 2013 • In the very elderly (age ≥ 80), the target for SBP should be < 150 (grade C) • No changes for those age 65-79; ie goal remains at < 140/90 Europe 2013 • In elderly < 80 years old with SBP ≥160 mmHg there is solid evidence to reducing SBP to 150 and 140 mmHg (IA) • In fit elderly patien ...
Gentamicin Dosing And Therapeutic Drug Monitoring Guideline
... Gentamicin has a potentially toxic side effect profile (nephrotoxicity and ototoxicity. Gentamicin should be used with caution in any patients with an impaired renal function. Due to a reduced rate of drug clearance and the potential for accumulation, this group of patients is particularly susceptib ...
... Gentamicin has a potentially toxic side effect profile (nephrotoxicity and ototoxicity. Gentamicin should be used with caution in any patients with an impaired renal function. Due to a reduced rate of drug clearance and the potential for accumulation, this group of patients is particularly susceptib ...
Drug treatment of hypertensive emergencies
... limited to the treatment of severe hypertension due to increased catecholamine activity. Examples include pheochromocytoma and tyramine ingestion in a patient being treated with a monoamine oxidase inhibitor. (See "Clinical presentation and diagnosis of pheochromocytoma" and see "Treatment of pheoch ...
... limited to the treatment of severe hypertension due to increased catecholamine activity. Examples include pheochromocytoma and tyramine ingestion in a patient being treated with a monoamine oxidase inhibitor. (See "Clinical presentation and diagnosis of pheochromocytoma" and see "Treatment of pheoch ...
product monograph trusopt
... The following drug interaction has been associated with the dorzolamide component of TRUSOPT® or with other sulfonamides: Acid-base Disturbances TRUSOPT® is a carbonic anhydrase inhibitor and although administered topically, is absorbed systemically. In clinical studies, TRUSOPT® was not associated ...
... The following drug interaction has been associated with the dorzolamide component of TRUSOPT® or with other sulfonamides: Acid-base Disturbances TRUSOPT® is a carbonic anhydrase inhibitor and although administered topically, is absorbed systemically. In clinical studies, TRUSOPT® was not associated ...
DARAPRIM® (pyrimethamine) 25 mg tablets Rx Only
... DARAPRIM did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an eld ...
... DARAPRIM did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an eld ...
Long Term Study of Ritalin
... psychostimulants. However, little long-term evidence is available, and controversy remains about whether these conditions are worsened by stimulant use." The authors state that the most prominent long term side effect was decreased appetite: "The current data also documented that stimulant medicatio ...
... psychostimulants. However, little long-term evidence is available, and controversy remains about whether these conditions are worsened by stimulant use." The authors state that the most prominent long term side effect was decreased appetite: "The current data also documented that stimulant medicatio ...
activase-prescribing-information
... During and following Activase administration for the treatment of acute ischemic stroke, frequently monitor and control blood pressure. In patients without recent use of oral anticoagulants or heparin, Activase treatment can be initiated prior to the availability of coagulation study results. Discon ...
... During and following Activase administration for the treatment of acute ischemic stroke, frequently monitor and control blood pressure. In patients without recent use of oral anticoagulants or heparin, Activase treatment can be initiated prior to the availability of coagulation study results. Discon ...
Oral AntiCoagulants
... fibrillation. Published in 2009, the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial was a non-inferiority study randomizing 18,000 patients with nonvalvular AF and a moderate-to-high risk of thromboembolic stroke to either high- or low-dose dabigatran or to warfarin. ...
... fibrillation. Published in 2009, the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial was a non-inferiority study randomizing 18,000 patients with nonvalvular AF and a moderate-to-high risk of thromboembolic stroke to either high- or low-dose dabigatran or to warfarin. ...
QA50_8_Hypersalivationgeneral
... Accessed via http://www.nice.org.uk/guidance/cg35/evidence on 1st July 2015. Lewis DW, Fontana C, Mehallick LK et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994;36:484-486. Mato A, Limeres J, Tomas I et al. Management of drooling ...
... Accessed via http://www.nice.org.uk/guidance/cg35/evidence on 1st July 2015. Lewis DW, Fontana C, Mehallick LK et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994;36:484-486. Mato A, Limeres J, Tomas I et al. Management of drooling ...
COO (CHOH)2•2½H2O COOH CH2 CH2 OCH3 O O HN±CH3 CH3
... is excreted in the urine, 50% to 60% as metabolites and approximately 15% as unchanged drug and conjugate. The plasma half-life is 2.2 hours. Special Populations No significant pharmacokinetic differences based on age or gender have been demonstrated. The pharmacokinetics of hydrocodone and ibuprofe ...
... is excreted in the urine, 50% to 60% as metabolites and approximately 15% as unchanged drug and conjugate. The plasma half-life is 2.2 hours. Special Populations No significant pharmacokinetic differences based on age or gender have been demonstrated. The pharmacokinetics of hydrocodone and ibuprofe ...
AUGMENTIN SUSPENSION 228 MG/5 ml and 457 MG/5 ml
... Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the ...
... Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the ...
Sitagliptin Phosphate
... gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as dictated by the patient’s clinical status. Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemod ...
... gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as dictated by the patient’s clinical status. Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemod ...
Suggestion from clinicians
... (RR, 0.90; 95% CI, 0.85-0.95; P ¼ 0.0003). Comparison of the lower-dose regimens with warfarin showed similar rates of stroke or systemic embolism, significantly less intracranial bleeding, and significantly less mortality. Based on these observations coupled with greater convenience for patients an ...
... (RR, 0.90; 95% CI, 0.85-0.95; P ¼ 0.0003). Comparison of the lower-dose regimens with warfarin showed similar rates of stroke or systemic embolism, significantly less intracranial bleeding, and significantly less mortality. Based on these observations coupled with greater convenience for patients an ...
CLEXANE and CLEXANE FORTE
... did not exhibit venous thromboembolic disease (either by negative venography in one study or by absence of clinical signs or symptoms in the other study) at the completion of in-hospital treatment were randomised to receive extended prophylaxis with either CLEXANE (n = 221) or placebo (n = 220) post ...
... did not exhibit venous thromboembolic disease (either by negative venography in one study or by absence of clinical signs or symptoms in the other study) at the completion of in-hospital treatment were randomised to receive extended prophylaxis with either CLEXANE (n = 221) or placebo (n = 220) post ...
cdph/oa/adap - Magellan Rx
... Refills may be obtained after 80 percent of the previously dispensed days’ supply has been used; however, there is an annual maximum of 13 fills per prescription. ...
... Refills may be obtained after 80 percent of the previously dispensed days’ supply has been used; however, there is an annual maximum of 13 fills per prescription. ...
Abstral sublingual tablet ENG SmPC
... intensity with continued use. The most serious potential adverse reactions associated with opioid use are respiratory depression (which could lead to respiratory arrest), hypotension and shock. The clinical trials of Abstral were designed to evaluate safety and efficacy in treating patients with bre ...
... intensity with continued use. The most serious potential adverse reactions associated with opioid use are respiratory depression (which could lead to respiratory arrest), hypotension and shock. The clinical trials of Abstral were designed to evaluate safety and efficacy in treating patients with bre ...
Adreno-cortico-steroids, Inhibitors, and Antagonists
... ➨ Describe the main features of the pharmacokinetics of corticosteroids. ➨ List the routes of administration of corticosteroids. ➨ Describe the adverse effects of glucocorticoids after acute or long-term administration. ➨ List the main microorganisms that can cause an infection in patients receiving ...
... ➨ Describe the main features of the pharmacokinetics of corticosteroids. ➨ List the routes of administration of corticosteroids. ➨ Describe the adverse effects of glucocorticoids after acute or long-term administration. ➨ List the main microorganisms that can cause an infection in patients receiving ...
Analgesia and sedation in emergency situations and in the pediatric
... A water-soluble agent with a rapid onset of action. It is an anxiolytic, inducing rapid sedation and its main advantage is that it causes short-term memory loss. It is four times more powerful than diazepam. Respiratory depression is dose-dependent and hypotension might occur in hypovolemic patients ...
... A water-soluble agent with a rapid onset of action. It is an anxiolytic, inducing rapid sedation and its main advantage is that it causes short-term memory loss. It is four times more powerful than diazepam. Respiratory depression is dose-dependent and hypotension might occur in hypovolemic patients ...
A1982NB74800001
... the lowerlimits of assay sensitivity. We thus set up a joint study to explore the concept of the ‘beta blocking dose’ and the kinetics of propranolol using 14C labelled drugs. This was an exciting project in which the expertise and resources of the academic department at the Royal Postgraduate Medic ...
... the lowerlimits of assay sensitivity. We thus set up a joint study to explore the concept of the ‘beta blocking dose’ and the kinetics of propranolol using 14C labelled drugs. This was an exciting project in which the expertise and resources of the academic department at the Royal Postgraduate Medic ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.